 we report on our fourth quarter and year-end financial results and provide a snap shot of our financial position and review the upcoming investor conference calendar. on the call today we have Dr. Sophia Miller, our president and chief executive officer, and we also have our chief operating officer, who is also our chief scientific officer.    
 we will begin with an overview of the fourth quarter and more recent highlights and developments at Abeona. then we will turn the call over to our two lead gene therapy programs in the form of autologous keratinocyte corrective gene therapy for a horrifying disease called epidermolysis bullosa and a lysosomal storage disease called Sanfilippo syndrome type a. we will then provide an update on the status of these programs as well as our plans for 2017 and beyond.    
 finally we will open the floor up for questions.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 